BCL2 and Miyoshi myopathy: MM cells with the t(11;14) translocation tend to express a higher ratio of Bcl-2 to Mcl-1 (Mcl1 being a resistance factor).40 Other preclinical studies thus far have shown that venetoclax administered in combination with melphalan or carfilzomib produces additive effects in a number of cell lines, especially when given with dexamethasone.